Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 10 2020
Historique:
pubmed: 14 8 2020
medline: 24 2 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

Sensitive outcome measures for disease progression are needed for treatment trials in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). To quantify photoreceptor degeneration outside regions of GA in eyes with nonexudative AMD, to evaluate its association with future GA progression, and to characterize its spatio-temporal progression. Monocenter cohort study (Directional Spread in Geographic Atrophy [NCT02051998]) and analysis of data from a normative data study at a tertiary referral center. One hundred fifty-eight eyes of 89 patients with a mean (SD) age of 77.7 (7.1) years, median area of GA of 8.87 mm2 (IQR, 4.09-15.60), and median follow-up of 1.1 years (IQR, 0.52-1.7 years), as well as 93 normal eyes from 93 participants. Longitudinal spectral-domain optical coherence tomography (SD-OCT) volume scans (121 B-scans across 30° × 25°) were segmented with a deep-learning pipeline and standardized in a pointwise manner with age-adjusted normal data (z scores). Outer nuclear layer (ONL), photoreceptor inner segment (IS), and outer segment (OS) thickness were quantified along evenly spaced contour lines surrounding GA lesions. Linear mixed models were applied to assess the association between photoreceptor-related imaging features and GA progression rates and characterize the pattern of photoreceptor degeneration over time. Association of ONL thinning with follow-up time (after adjusting for age, retinal topography [z score], and distance to the GA boundary). The study included 158 eyes of 89 patients (51 women and 38 men) with a mean (SD) age of 77.7 (7.1) years. The fully automated B-scan segmentation was accurate (dice coefficient, 0.82; 95% CI, 0.80-0.85; compared with manual markings) and revealed a marked interpatient variability in photoreceptor degeneration. The ellipsoid zone (EZ) loss-to-GA boundary distance and OS thickness were prognostic for future progression rates. Outer nuclear layer and IS thinning over time was significant even when adjusting for age and proximity to the GA boundary (estimates of -0.16 μm/y; 95% CI, -0.30 to -0.02; and -0.17 μm/y; 95% CI, -0.26 to -0.09). Distinct and progressive alterations of photoreceptor laminae (exceeding GA spatially) were detectable and quantifiable. The degree of photoreceptor degeneration outside of regions of retinal pigment epithelium atrophy varied markedly between eyes and was associated with future GA progression. Macula-wide photoreceptor laminae thinning represents a potential candidate end point to monitor treatment effects beyond mere GA lesion size progression.

Identifiants

pubmed: 32789526
pii: 2769185
doi: 10.1001/jamaophthalmol.2020.2914
pmc: PMC7426886
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1026-1034

Références

Eye (Lond). 2018 Dec;32(12):1819-1830
pubmed: 30068928
Biomed Opt Express. 2017 Apr 27;8(5):2732-2744
pubmed: 28663902
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO121-BIO130
pubmed: 28632841
Am J Ophthalmol. 2018 Jun;190:1-8
pubmed: 29530781
Retina. 2017 Jul;37(7):1329-1336
pubmed: 28633153
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD160-AMD181
pubmed: 30357336
Ophthalmology. 2013 Dec;120(12):2630-2636
pubmed: 23830760
Am J Ophthalmol. 2007 Mar;143(3):463-72
pubmed: 17239336
Ophthalmic Surg Lasers Imaging Retina. 2013 Jul-Aug;44(4):344-59
pubmed: 23883530
Retina. 2013 Oct;33(9):1800-8
pubmed: 23764969
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2079-2086
pubmed: 28388704
J Clin Invest. 2014 Apr;124(4):1430-8
pubmed: 24691477
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4632-4643
pubmed: 28898357
Am J Ophthalmol. 2016 Aug;168:52-61
pubmed: 27163235
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD122-AMD131
pubmed: 30140905
Retina. 2020 Apr;40(4):618-631
pubmed: 31599795
Surv Ophthalmol. 2018 Nov - Dec;63(6):782-815
pubmed: 29859199
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD12-AMD18
pubmed: 29558533
Ophthalmology. 2018 Jun;125(6):842-849
pubmed: 29366564
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3992-4001
pubmed: 31560765
Ophthalmology. 2015 Jul;122(7):1356-65
pubmed: 25972258
Am J Ophthalmol. 2020 Jun;214:172-187
pubmed: 31843474
Ophthalmol Retina. 2020 Mar;4(3):274-283
pubmed: 31924545
Pharmacotherapy. 2013 Aug;33(8):838-55
pubmed: 23580402
Ophthalmol Retina. 2020 Mar;4(3):238-248
pubmed: 31753808
Ophthalmology. 2019 Jan;126(1):55-63
pubmed: 30077616
Ophthalmology. 2007 Sep;114(9):1728-35
pubmed: 17822978
Retina. 2019 Aug;39(8):1527-1540
pubmed: 29781974
Am J Ophthalmol. 2016 Aug;168:260-268
pubmed: 27296489
JAMA Ophthalmol. 2018 Jun 1;136(6):666-677
pubmed: 29801123
Comput Biol Med. 2014 Nov;54:116-28
pubmed: 25240102
Am J Ophthalmol. 2018 Sep;193:166-177
pubmed: 29981740
PLoS One. 2019 Feb 22;14(2):e0212563
pubmed: 30794627
Sci Rep. 2019 Jul 31;9(1):11132
pubmed: 31366903
Ophthalmology. 2016 Aug;123(8):1737-1750
pubmed: 27262765
Ophthalmology. 2013 Dec;120(12):2666-2671
pubmed: 24206616
Invest Ophthalmol Vis Sci. 2020 May 11;61(5):63
pubmed: 32462198
PLoS One. 2019 Aug 16;14(8):e0220063
pubmed: 31419240
Retina. 2016 Dec;36 Suppl 1:S26-S39
pubmed: 28005661
Retina. 2020 Jan;40(1):169-180
pubmed: 30300264
Ophthalmol Retina. 2019 Jun;3(6):478-488
pubmed: 31174669
Ophthalmol Retina. 2019 Apr;3(4):316-325
pubmed: 31014683
Ophthalmology. 2019 Dec;126(12):1659-1666
pubmed: 31558345
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2463-71
pubmed: 27149696
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7640-6
pubmed: 21873669
Retina. 2018 Oct;38(10):1937-1953
pubmed: 29746415
Am J Ophthalmol. 2020 Sep;217:162-173
pubmed: 32289293
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO61-BIO67
pubmed: 28475704

Auteurs

Maximilian Pfau (M)

Department of Biomedical Data Science, Stanford University, Stanford, California.
Department of Ophthalmology, University of Bonn, Bonn, Germany.

Leon von der Emde (L)

Department of Ophthalmology, University of Bonn, Bonn, Germany.

Luis de Sisternes (L)

Research and Development, Carl Zeiss Meditec Inc, Dublin, California.

Joelle A Hallak (JA)

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago.

Theodore Leng (T)

Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California.

Steffen Schmitz-Valckenberg (S)

Department of Ophthalmology, University of Bonn, Bonn, Germany.
John A. Moran Eye Center, University of Utah, Salt Lake City.

Frank G Holz (FG)

Department of Ophthalmology, University of Bonn, Bonn, Germany.

Monika Fleckenstein (M)

Department of Ophthalmology, University of Bonn, Bonn, Germany.
John A. Moran Eye Center, University of Utah, Salt Lake City.

Daniel L Rubin (DL)

Department of Biomedical Data Science, Stanford University, Stanford, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH